تاثیر عصاره بایکالین، فعال‌کننده بر تمایز اریتروییدی سلول‌های بنیادی خونساز CD133 بند ناف

Abstractbackground and objectivesthe effect of baicalin, a ppary activator, was investigated on erythroid differentiation of cd133+ cord blood hematopoietic stem cells.materials and methodsthe effect of ppar? agonists (baicalin and troglitazone) were evaluated in erythropoiesis. cd133+ cells were isolated from human cord blood using macs technology and cultured in the medium containing ppar? agonists in a dose-dependent manner with scf (20 ng/ml) and epo (4.5 u/ml). the morphology of cd133+ cells, cell surface markers (transferrin receptor and glycophorin a), and the formation of erythroid colony were assessed with microscopicanalysis, flow cytometry, and colony forming assay, respectively.resultsmicroscopic and flow cytometric analysis revealed the differentiation of cd133+ cord blood hematopoietic stem cells to erythroid lineage. flow cytometry showed that both of the ppar? agonists were able to diminish significantly transferrin receptor and glycophorin a positive cell population. the inhibitory effect of ppar? agonists on erythroid differentiation was dose-dependent. the colonies formation of erythroid was suppressed by both of ppary agonists; hence, the effect of troglitazone was markedly higher. the inhibitory effect of troglitazone on colonies formation of erythroid was also markedly higher than bicaline.conclusions our findings demonstrated that ppary agonists modulates erythroid differentiation of cd133+ hematopoietic stem cell; therefore, they might play an important role in regulating normal erythropoiesis in vivo. the inhibitory effect of baicalin on erythropoiesis should be noted because this herbal remedy mostly is used to treat a wide range of diseases.